Results 141 to 150 of about 59,985 (224)

Basophil Activation and Histamine Release Tests in Relation to Omalizumab Response in Peanut‐Allergic Children

open access: yes
Clinical &Experimental Allergy, EarlyView.
Christian Nielsen   +3 more
wiley   +1 more source

Type 2 Inflammation and Its Role in Dermatologic Diseases

open access: yesInternational Journal of Dermatology, EarlyView.
ABSTRACT Atopic dermatitis, prurigo nodularis, and chronic spontaneous urticaria are immune‐mediated, inflammatory skin conditions characterized by intense itch and disease‐specific skin lesions. Despite their different clinical presentations, the three diseases are unified by an aberrant type 2 immune response involving type 2 cytokines, immune cells,
Raj Chovatiya   +5 more
wiley   +1 more source

Climate Justice Strategies Implemented by Public Health Nurses and Their Community Partners

open access: yesJournal of Advanced Nursing, EarlyView.
ABSTRACT Aim To describe nurses' and community‐based organization representatives' collaborative strategies for advancing climate justice with communities. Design This study used a descriptive, qualitative research design. Methods Data were gathered from August 2022 to February 2023 with nurses (n = 8) and their community partners (n = 5) in the United
Jessica LeClair   +2 more
wiley   +1 more source

European Guideline (EuroGuiDerm) on atopic eczema: Living update

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
The updated guideline includes a new evidence‐based recommendation for the IL‐13 inhibitor lebrikizumab. In addition, the Janus kinase inhibitors baricitinib and abrocitinib, which were initially only approved for adult patients, are now also recommended for children from the age of 2 and adolescents from the age of 12, respectively.
A. Wollenberg   +31 more
wiley   +1 more source

Severe Asthma and Active SARS-CoV-2 Infection: Insights into Biologics. [PDF]

open access: yesBiomedicines
Manti S   +5 more
europepmc   +1 more source

Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This cohort study of 1793 atopic dermatitis patients (aged ≥ 12) found higher infection rates with Janus kinase inhibitor treatment compared to biologic treatment, particularly for herpes infections, with a history of viral or fungal skin infection as a risk factor associated with infection.
Lian F. van der Gang   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy